Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940240 | 0.86 | TRPV1 (0.80) | TRPV1ALDH1A1 | |
| SCHEMBL10424971 | 0.86 | TRPV1 (0.57) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL8618533 | 0.85 | TRPV1 (0.78) | TRPV1ALDH1A1 | |
| SCHEMBL8618528 | 0.85 | TRPV1 (0.78) | TRPV1ALDH1A1 | |
| SCHEMBL2833266 | 0.84 | TRPV1 (0.56) | TRPV1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL5925543 | 0.84 | LMNA (0.61) | TRPV1TSHRALDH1A1LMNACYP1A2 | |
| Benzoic Acid 3-Methyl-2-Butenyl Ester SCHEMBL873002 | 0.84 | TRPV1 (0.55) | TRPV1TSHRALDH1A1SLC6A2TDP1 | |
| SCHEMBL5301347 | 0.81 | ALDH1A1 (0.55) | TRPV1TSHRALDH1A1MAPK1LMNA | |
| SCHEMBL27871910 | 0.81 | CA12 (0.63) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL31182 | 0.78 | SNCA (0.59) | ESR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035981-A1 | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment | MAZZIO ELIZABETH A | 2006-02-16 | — | — | US | claimed |
| WO-2006017494-A2 | INHIBITION OF ANAEROBIC GLUCOSE METABOLISM | MAZZIO ELIZABETH (US) | 2006-02-16 | — | — | WO | claimed |
| CN-115725067-B | Preparation method of high-workability sulfonic acid group monomer for synthesizing polycarboxylate superplasticizer monomer through micro-channels | 抚顺东科精细化工有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-103608323-B | The method for the treatment of central nerve neuroma | 博格有限责任公司 | 2016-08-17 | — | — | CN | disclosed |
| US-8802161-B2 | Herbal composition and method of use for the treatment of cancer | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| CN-103608323-A | Methods of treating central nervous system tumors | BERG PHARMA LLC | 2014-02-26 | — | — | CN | disclosed |
| CN-102481269-A | Methods of treating diseases using epimetabolic shifters (coenzyme Q10) | CYTOTECH LABS LLC | 2012-05-30 | — | — | CN | disclosed |
| CN-102483419-A | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | CYTOTECH LABS LLC | 2012-05-30 | — | — | CN | disclosed |
| CN-102481270-A | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | CYTOTECH LABS LLC | 2012-05-30 | — | — | CN | disclosed |
| CN-102481271-A | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | CYTOTECH LABS LLC | 2012-05-30 | — | — | CN | disclosed |
| US-20100209388-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | FLORIDA A & M UNIVERSITY | 2010-08-19 | — | — | US | disclosed |
| US-20070248693-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | MAZZIO ELIZABETH | 2007-10-25 | — | — | US | disclosed |
| US-20060068386-A1 | Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof | SLESAREV ALEXEI | 2006-03-30 | — | — | US | disclosed |
| US-20060035981-A1 | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment | MAZZIO ELIZABETH A | 2006-02-16 | — | — | US | disclosed |
| WO-2006017494-A2 | INHIBITION OF ANAEROBIC GLUCOSE METABOLISM | MAZZIO ELIZABETH (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209388-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | DLD, MDH1, MDH2 | ESR1 2921/4885CA12 638/4885CA1 561/4885 |
| US-20060035981-A1 | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment | G6PD, PDK2, SDHA | ESR1 3164/4885CA12 2801/4885CA1 1905/4885 |
| US-20070248693-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | DLD, DERA, ALDOA | ESR1 4232/4885CA12 2018/4885CA1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.